KR20220164473A - 생체외 감마 델타 t 세포 집단 - Google Patents
생체외 감마 델타 t 세포 집단 Download PDFInfo
- Publication number
- KR20220164473A KR20220164473A KR1020227029501A KR20227029501A KR20220164473A KR 20220164473 A KR20220164473 A KR 20220164473A KR 1020227029501 A KR1020227029501 A KR 1020227029501A KR 20227029501 A KR20227029501 A KR 20227029501A KR 20220164473 A KR20220164473 A KR 20220164473A
- Authority
- KR
- South Korea
- Prior art keywords
- seq
- cells
- antibody
- optionally
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2002581.3A GB202002581D0 (en) | 2020-02-24 | 2020-02-24 | Novel antibodies |
| GB2002581.3 | 2020-02-24 | ||
| PCT/GB2021/050460 WO2021171003A1 (en) | 2020-02-24 | 2021-02-24 | Ex vivo gamma delta t cell populations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220164473A true KR20220164473A (ko) | 2022-12-13 |
Family
ID=70108379
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227029501A Pending KR20220164473A (ko) | 2020-02-24 | 2021-02-24 | 생체외 감마 델타 t 세포 집단 |
| KR1020227033455A Pending KR20220145894A (ko) | 2020-02-24 | 2021-02-24 | 신규 항체 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227033455A Pending KR20220145894A (ko) | 2020-02-24 | 2021-02-24 | 신규 항체 |
Country Status (17)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202006989D0 (en) * | 2020-05-12 | 2020-06-24 | Gammadelta Therapeutics Ltd | Methods for isolating gamma delta t cells |
| KR20230160253A (ko) | 2021-02-17 | 2023-11-23 | 감마델타 테라퓨틱스 엘티디 | 항-tcr 델타 가변 1 항체 |
| MX2023009544A (es) | 2021-02-17 | 2023-11-28 | Gammadelta Therapeutics Ltd | Anticuerpos anti-variable delta 1 de tcr multiespecíficos. |
| CN119080924B (zh) * | 2024-07-04 | 2025-02-25 | 上海交通大学医学院附属第九人民医院 | 一种单克隆免疫球蛋白及其用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003210060B2 (en) | 2002-03-22 | 2010-02-25 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| CN100591761C (zh) | 2004-08-19 | 2010-02-24 | 加的夫大学学院咨询有限公司 | 呈递抗原的人γδT细胞的制备和在免疫治疗中的用途 |
| CN102453701B (zh) * | 2010-10-26 | 2014-08-13 | 中国医学科学院基础医学研究所 | 基因修饰CDR3δ移植型γδT淋巴细胞及其抑癌用途 |
| CN105859889B (zh) | 2010-11-17 | 2020-01-07 | 中外制药株式会社 | 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子 |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| GB201506423D0 (en) | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| RU2756247C2 (ru) * | 2014-11-17 | 2021-09-28 | Эдисет Био, Инк. | Генетически модифицированные гамма дельта т-клетки |
| GB201507368D0 (en) * | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| JP6799895B2 (ja) * | 2015-06-09 | 2020-12-16 | リンファクト−リンフォサイト アクティベイション テクノロジーズ エス.エー. | TCRγδ+T細胞の生産方法 |
| US10946095B2 (en) | 2015-09-02 | 2021-03-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT) |
| US10456211B2 (en) | 2015-11-04 | 2019-10-29 | Medicrea International | Methods and apparatus for spinal reconstructive surgery and measuring spinal length and intervertebral spacing, tension and rotation |
| PE20190115A1 (es) | 2016-04-15 | 2019-01-16 | Immunext Inc | Anticuerpos vista antihumanos y su uso |
| CN118421557A (zh) | 2016-05-12 | 2024-08-02 | 阿迪塞特治疗公司 | 选择性扩增γδT细胞群的方法及其组合物 |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| WO2019005637A2 (en) | 2017-06-25 | 2019-01-03 | Systimmune, Inc. | MULTIPECIFIC ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF |
| WO2019147735A1 (en) | 2018-01-23 | 2019-08-01 | New York University | Antibodies specific to delta 1 chain of t cell receptor |
| JP7457007B2 (ja) | 2018-09-19 | 2024-03-27 | ラヴァ・セラピューティクス・エヌ・ヴイ | 二重作用CD1d免疫グロブリン |
| GB201818243D0 (en) | 2018-11-08 | 2018-12-26 | Gammadelta Therapeutics Ltd | Methods for isolating and expanding cells |
| CA3127103A1 (en) | 2019-01-23 | 2020-07-30 | New York University | Antibodies specific to delta 1 chain of t cell receptor |
| WO2020159368A1 (en) | 2019-02-01 | 2020-08-06 | Lava Therapeutics B.V. | Novel cd40-binding antibodies |
| CA3136251A1 (en) | 2019-04-08 | 2020-10-15 | Memorial Sloan Kettering Cancer Center | Cd19 antibodies and methods of using the same |
| CA3148588A1 (en) | 2019-08-16 | 2021-02-25 | GammaDelta Therapeutics Limited | Ex vivo gamma delta t cell populations |
| JP2022545196A (ja) * | 2019-08-16 | 2022-10-26 | ガンマデルタ セラピューティクス リミテッド | 抗tcrデルタ可変1抗体の治療的使用 |
| GB2586487B (en) | 2019-08-21 | 2024-03-06 | Bae Systems Plc | Materials Classifier |
| MX2023009544A (es) | 2021-02-17 | 2023-11-28 | Gammadelta Therapeutics Ltd | Anticuerpos anti-variable delta 1 de tcr multiespecíficos. |
| KR20230160253A (ko) | 2021-02-17 | 2023-11-23 | 감마델타 테라퓨틱스 엘티디 | 항-tcr 델타 가변 1 항체 |
-
2020
- 2020-02-24 GB GBGB2002581.3A patent/GB202002581D0/en not_active Ceased
-
2021
- 2021-02-24 EP EP21709757.5A patent/EP4110813A1/en active Pending
- 2021-02-24 JP JP2022550778A patent/JP2023516925A/ja active Pending
- 2021-02-24 AU AU2021228266A patent/AU2021228266A1/en active Pending
- 2021-02-24 IL IL295696A patent/IL295696A/en unknown
- 2021-02-24 MX MX2022010383A patent/MX2022010383A/es unknown
- 2021-02-24 CN CN202180028136.1A patent/CN115697401A/zh active Pending
- 2021-02-24 US US17/904,890 patent/US20230159638A1/en active Pending
- 2021-02-24 CA CA3168973A patent/CA3168973A1/en active Pending
- 2021-02-24 KR KR1020227029501A patent/KR20220164473A/ko active Pending
- 2021-02-24 PE PE2022001812A patent/PE20230438A1/es unknown
- 2021-02-24 US US17/801,786 patent/US12698328B2/en active Active
- 2021-02-24 AU AU2021225390A patent/AU2021225390A1/en active Pending
- 2021-02-24 BR BR112022016894A patent/BR112022016894A2/pt unknown
- 2021-02-24 EP EP25177102.8A patent/EP4591882A3/en active Pending
- 2021-02-24 KR KR1020227033455A patent/KR20220145894A/ko active Pending
- 2021-02-24 EP EP21709758.3A patent/EP4110387B1/en active Active
- 2021-02-24 CN CN202180030584.5A patent/CN115461369A/zh active Pending
- 2021-02-24 MX MX2022010239A patent/MX2022010239A/es unknown
- 2021-02-24 WO PCT/GB2021/050460 patent/WO2021171003A1/en not_active Ceased
- 2021-02-24 IL IL295852A patent/IL295852A/en unknown
- 2021-02-24 WO PCT/GB2021/050459 patent/WO2021171002A1/en not_active Ceased
- 2021-02-24 BR BR112022016671A patent/BR112022016671A2/pt unknown
- 2021-02-24 JP JP2022550813A patent/JP7858536B2/ja active Active
- 2021-02-24 CA CA3172340A patent/CA3172340A1/en active Pending
-
2022
- 2022-08-23 CL CL2022002296A patent/CL2022002296A1/es unknown
- 2022-08-30 ZA ZA2022/09699A patent/ZA202209699B/en unknown
- 2022-09-21 CO CONC2022/0013542A patent/CO2022013542A2/es unknown
- 2022-09-22 CO CONC2022/0013633A patent/CO2022013633A2/es unknown
- 2022-09-22 EC ECSENADI202274030A patent/ECSP22074030A/es unknown
-
2026
- 2026-01-20 JP JP2026007486A patent/JP2026086466A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113039205B (zh) | 靶向cll1的抗体及其应用 | |
| JP7764364B2 (ja) | エクスビボγδ T細胞集団 | |
| JP2026009903A (ja) | 新規な抗tcrデルタ可変1抗体 | |
| AU2016339832B2 (en) | Antibody agents specific for human CD19 and uses thereof | |
| KR20180132751A (ko) | Bcma 결합 분자 및 그의 사용 방법 | |
| KR102439395B1 (ko) | Ilt7 결합 분자 및 이의 사용 방법 | |
| JP7858536B2 (ja) | Ex vivoガンマデルタt細胞集団 | |
| KR20210046725A (ko) | 신규 암 면역요법 항체 조성물 | |
| HK40084452A (en) | Novel antibodies | |
| RU2804490C2 (ru) | Новые композиции антител для иммунотерапии рака | |
| HK40130434A (en) | Ex vivo gamma delta t cell populations | |
| EA052465B1 (ru) | Популяции гамма-дельта т-клеток ex vivo | |
| HK40075692A (en) | Novel anti-tcr delta variable 1 antibodies | |
| WO2025031290A1 (zh) | 抗ox40l抗体以及其用途 | |
| HK40086246A (en) | Ex vivo gamma delta t cell populations | |
| HK40086246B (en) | Ex vivo gamma delta t cell populations | |
| HK40047112B (en) | Novel cancer immunotherapy antibody compositions | |
| HK40116575B (en) | Anti-cd40 antibody, anti-pd-l1×cd40 bispecific antibody, and use thereof | |
| HK1241907A1 (en) | Antibody agents specific for human cd19 and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R17-X000 | Change to representative recorded |
St.27 status event code: A-3-3-R10-R17-oth-X000 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |